Company: SWKH
Filing Date: 2025-04-29
Form Type: ARS
Source: 0001628280-25-020753
Chunk: 60

Company: SWK Holdings Corp
Filing Date: 2025-04-29
Form: ARS
Chunk 60
---
     |                         |   5,236 |       |     |   |   6,156 |       |
| Cash, cash equivalents, and restricted cash at end of period                                   |     |                         |         | 5,927 |     |   |         | 5,236 |
| Supplemental non-cash investing and financing activities:                                      |     |                         |         |       |     |   |         |       |
| Derecognition of right-of-use assets and operating lease liabilities upon termination of lease |     |                         |      82 |       |     |   |       — |       |
| Cash paid for interest                                                                         |     | $                       |   3,082 |       |     | $ |   1,351 |       |
| Fair value of warrants received with finance receivables                                       |     | $                       |   1,241 |       |     | $ |   1,364 |       |

<div align='center'>See accompanying notes to the consolidated financial statements.

37</div>

### SWK HOLDINGS CORPORATION

### NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Note 1. SWK Holdings Corporation and Summary of Significant Accounting Policies

### Nature of Operations
SWK Holdings Corporation (the “Company,” “we,” or “us”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, we commenced a strategy of building a specialty finance and asset management business. In August 2019, we commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business. Our operations comprise two reportable segments: “Finance Receivables” and “Pharmaceutical Development.” We evaluate and invest in a broad range of healthcare related companies and products with innovative intellectual property, including the biotechnology, medical device, medical diagnostics and related tools, animal health and pharmaceutical industries (collectively, “life sciences”). We allocate capital to each segment in order to generate income through the sales of life science products by third parties and related earned income sources. The Company is headquartered in Dallas, Texas, and as of December 31, 2024, the Company had 24 full-time employees.

The Company has net operating loss carryforwards (“NOLs”) and believes that the ability to utilize these NOLs is an important and substantial asset.

As of March 7, 2025, the Company and its partners have executed transactions with 58